Patents by Inventor Roshantha Chandraratna

Roshantha Chandraratna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11793781
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: October 24, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • RAR selective agonists in combination with immune modulators for cancer immunotherapy
    Patent number: 11786555
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11779558
    Abstract: Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 10, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20230310354
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: April 28, 2023
    Publication date: October 5, 2023
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20230293506
    Abstract: The present specification provides methods of treating a transplant rejection, pulmonary fibrosis, or glomerulonephritis with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 21, 2023
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11737996
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690832
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690831
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 11648222
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 16, 2023
    Assignees: IO Therapeutics, Inc., The Johns Hopkins Univercity
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11648223
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: May 16, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
    Publication number: 20230129034
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Application
    Filed: November 2, 2022
    Publication date: April 27, 2023
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
    Publication number: 20230126763
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Application
    Filed: November 2, 2022
    Publication date: April 27, 2023
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11576881
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: February 14, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11547684
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: January 10, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of disease with esters of selective RXR agonists
    Patent number: 11517549
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 6, 2022
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS
    Publication number: 20220370386
    Abstract: The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
    Type: Application
    Filed: July 7, 2022
    Publication date: November 24, 2022
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20220184013
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20220184012
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
    Publication number: 20220151964
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 19, 2022
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20220143000
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders